These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 15131492)

  • 21. Baseline severity of depression predicts antidepressant drug response relative to escitalopram.
    Kilts CD; Wade AG; Andersen HF; Schlaepfer TE
    Expert Opin Pharmacother; 2009 Apr; 10(6):927-36. PubMed ID: 19317630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder.
    Schmitt L; Tonnoir B; Arbus C
    Neuropsychobiology; 2006; 54(4):201-7. PubMed ID: 17337913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.
    Wade A; Michael Lemming O; Bang Hedegaard K
    Int Clin Psychopharmacol; 2002 May; 17(3):95-102. PubMed ID: 11981349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram.
    Lançon C; Verpillat P; Annemans L; Despiegel N; François C
    Int J Psychiatry Clin Pract; 2007; 11(1):44-52. PubMed ID: 24941275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence based review of escitalopram in treating major depressive disorder in primary care.
    Einarson TR
    Int Clin Psychopharmacol; 2004 Sep; 19(5):305-10. PubMed ID: 15289704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
    Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis.
    Lam RW; Andersen HF
    Pharmacopsychiatry; 2006 Sep; 39(5):180-4. PubMed ID: 16944409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials.
    Trkulja V
    Croat Med J; 2010 Feb; 51(1):61-73. PubMed ID: 20162747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Escitalopram continuation treatment prevents relapse of depressive episodes.
    Rapaport MH; Bose A; Zheng H
    J Clin Psychiatry; 2004 Jan; 65(1):44-9. PubMed ID: 14744167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial.
    Kim JM; Bae KY; Stewart R; Jung BO; Kang HJ; Kim SW; Shin IS; Hong YJ; Kim JH; Shin HY; Kang G; Ahn Y; Kim JK; Jeong MH; Yoon JS
    J Clin Psychiatry; 2015 Jan; 76(1):62-8. PubMed ID: 25375836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram.
    Jacobsen PL; Nomikos GG; Zhong W; Cutler AJ; Affinito J; Clayton A
    CNS Spectr; 2020 Feb; 25(1):50-63. PubMed ID: 31010445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of escitalopram compared to citalopram: a meta-analysis.
    Montgomery S; Hansen T; Kasper S
    Int J Neuropsychopharmacol; 2011 Mar; 14(2):261-8. PubMed ID: 20875220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The onset of effect for escitalopram and its relevance for the clinical management of depression.
    Wade A; Friis Andersen H
    Curr Med Res Opin; 2006 Nov; 22(11):2101-10. PubMed ID: 17076970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial.
    Mohamed S; Osatuke K; Aslam M; Kasckow J
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):201-9. PubMed ID: 17062320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder.
    Kasper S; Ebert B; Larsen K; Tonnoir B
    Int J Neuropsychopharmacol; 2012 Jul; 15(6):715-25. PubMed ID: 22008735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.